Associated Papers
Novel druggable space in human KRAS G13D discovered using structural bioinformatics and a P-loop targeting monoclonal antibody.
Jungholm O et al.
Scientific Reports, 2024
39179604 (PubMed )
Supplement: 41598_2024_70217_MOESM1_ESM.docx
A KRAS wild type mutational status confers a survival advantage in pancreatic ductal adenocarcinoma.
Windon AL et al.
Journal of Gastrointestinal Oncology, 2018
The cornerstone K-RAS mutation in pancreatic adenocarcinoma: From cell signaling network, target genes, biological processes to therapeutic targeting.
Jonckheere N et al.
Critical Reviews in Oncology/hematology, 2017
Select a paper to view details